P-31 changes as a measure of therapy response in resistant and sensitive osteosarcomas implanted into nude mice.

OBJECTIVE To determine if changes in PCr/Pi and PME can be used to predict lack of tumor response to chemotherapy in a murine model of a chemotherapy-resistant human osteosarcoma. MATERIAL AND METHODS Cisplatin-resistant sublines were grown from high-grade cisplatin-sensitive human osteosarcoma. Surface coil localized 31P NMR spectroscopy of implanted cisplatin-resistant and sensitive osteosarcoma tumors in nude mice was performed. RESULTS A cisplatin-resistant subline of a sensitive human osteosarcoma was developed that was five times more resistant to cisplatin than the parent cell line. Our NMR data shows a statistically significant difference in the change in the PCr/Pi ratio after treatment between sensitive and resistant osteosarcomas at the alpha = 0.05 level. Changes in PME were seen in the sensitive tumors but were not statistically significant. CONCLUSIONS Changes in PCr/Pi predict lack of tumor treatment response in human osteosarcoma implanted into nude mice with a specificity of 70% and a sensitivity of 54%. Monitoring of PCr/Pi in human osteosarcoma patients may allow detection of response to chemotherapy before conventional imaging techniques.

[1]  B. Croker,et al.  Mesenchymal specificity of three new monoclonal antibodies generated to the osteosarcoma cell line 4444T. , 1991, Clinical immunology and immunopathology.

[2]  J. Denekamp The choice of experimental models in cancer research: The key to ultimate success or failure? , 1992, NMR in biomedicine.

[3]  W. Aue,et al.  Extremity bone tumors: evaluation by P-31 MR spectroscopy. , 1985, Radiology.

[4]  R. Lenkinski,et al.  Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy of Bone Tumors and Bone Marrow Disease , 1989, Investigative radiology.

[5]  V. Courtenay,et al.  The response to chemotherapy of a variety of human tumour xenografts. , 1983, British Journal of Cancer.

[6]  P. Chang Bayesian analysis revisited: a radiologist's survival guide. , 1989, AJR. American journal of roentgenology.

[7]  K. Wolf,et al.  31P nuclear magnetic resonance spectroscopy, histology and cytokinetics of a xenografted hypopharynx carcinoma following treatment with cisplatin: comparison in three sublines with increasing resistance. , 1991, British Journal of Cancer.

[8]  J. Rygaard,et al.  Immune-deficient animals in biomedical research , 1987 .

[9]  T. Ng,et al.  Faraday shield for surface-coil studies of subcutaneous tumors , 1982 .

[10]  W. J. Lorenz,et al.  Monitoring human tumor response to therapy by means of P-31 MR spectroscopy. , 1988, Radiology.

[11]  P. Köpf-Maier,et al.  31P NMR spectroscopy of a xenografted hypopharynx carcinoma: Effects of tumor growth and treatment with cisplatin on the tumor phosphorus metabolism, histology and cytokinetics , 1992, NMR in biomedicine.

[12]  D. Dorfman,et al.  Maximum-likelihood estimation of parameters of signal-detection theory and determination of confidence intervals—Rating-method data , 1969 .

[13]  M. Inaba,et al.  Pharmacokinetic Approach to Rational Therapeutic Doses for Human Tumor‐bearing Nude Mice , 1988, Japanese journal of cancer research : Gann.

[14]  J. Zheng,et al.  Immune-deficient animals in experimental medicine. , 1989 .

[15]  C E Metz,et al.  Some practical issues of experimental design and data analysis in radiological ROC studies. , 1989, Investigative radiology.

[16]  M. Clerici,et al.  Growth kinetics and in vivo radiosensitivity in nude mice of two subpopulations derived from a single human small cell carcinoma of the lung. , 1986, European journal of cancer & clinical oncology.

[17]  W. Negendank,et al.  Studies of human tumors by MRS: A review , 1992, NMR in biomedicine.

[18]  B. Croker,et al.  31P changes as a measure of therapy response in human osteosarcomas implanted into nude mice. , 1994, Magnetic resonance imaging.

[19]  J. Stack,et al.  Osteosarcoma: use of MR imaging and MR spectroscopy in clinical decision making. , 1989, Radiology.

[20]  I. Young,et al.  Osteosarcoma and other neoplasms of bone. Magnetic resonance spectroscopy to monitor therapy. , 1987, Archives of surgery.

[21]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[22]  R. R. Ernst,et al.  Application of Fourier Transform Spectroscopy to Magnetic Resonance , 1966 .

[23]  J. Evelhoch,et al.  Response-specific adriamycin sensitivity markers provided by in vivo 31P nuclear magnetic resonance spectroscopy in murine mammary adenocarcinomas. , 1987, Cancer research.

[24]  G. Rosen,et al.  Adjuvant chemotherapy of osteosarcoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Metz Basic principles of ROC analysis. , 1978, Seminars in nuclear medicine.